原发性渗出性淋巴瘤预后评分(PEL-PS):一种在HIV相关原发性渗出性淋巴瘤中验证的国际预后评分
研究基于国际真实世界训练集59例和验证集58例接受一线含蒽环类化疗的HIV相关原发性渗出性淋巴瘤患者,建立并验证PEL-PS。ECOG≥3和血红蛋白<8 g/dL为独立不良预后因素,评分0分与1-2分患者中位总生存期差异显著。
要点
- PEL-PS由ECOG≥3(HR=4.0)和血红蛋白<8 g/dL(HR=3.8)构成。
- 训练集评分0分中位OS 10.6年 vs 1-2分0.8年(p<0.0001)。
- 验证集评分0分中位OS 16.9年 vs 1-2分0.6年(p<0.0001)。
核心结论
- PEL-PS可识别HIV相关原发性渗出性淋巴瘤预后良好与不良的患者。
- 预后不良患者可能从新疗法中获益。
研究设计与样本
- 研究为国际真实世界训练集与验证集分析,训练集59例来自美国国家癌症研究所HIV与艾滋病恶性肿瘤分部及英国切尔西与威斯敏斯特医院国家HIV恶性肿瘤中心,2000年至2022年接受一线含蒽环类化疗。
- 验证集58例来自法国圣路易医院同期接受一线含蒽环类化疗的HIV相关原发性渗出性淋巴瘤患者。
主要发现
- 多变量Cox模型显示ECOG≥3(p=0.007;HR=4.0,95%CI:1.5-11.1)和血红蛋白<8 g/dL(p=0.006;HR=3.8,95%CI:1.5-9.7)与较低生存概率独立相关。
- 训练集中,无不良预后因素(评分0:血红蛋白≥8 g/dL且ECOG≤2,占48.1%)患者中位OS为10.6年,而有1-2个不良预后因素(评分1-2:血红蛋白<8 g/dL和/或ECOG≥3,占51.9%)患者中位OS为0.8年(p<0.0001)。
- 验证集中,PEL-PS评分0患者中位OS为16.9年,评分1-2患者中位OS为0.6年(p<0.0001)。
关键数值与推荐
- PEL-PS评分0:血红蛋白≥8 g/dL且ECOG≤2。
- PEL-PS评分1-2:血红蛋白<8 g/dL和/或ECOG≥3。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary effusion lymphoma (PEL) is an HIV-associated B-cell non-Hodgkin lymphoma (NHL) caused by Kaposi sarcoma herpesvirus (KSHV). There is no validated prognostic model in PEL, and prognosis is thought to be poor compared to other HIV-associated NHL. We derived the PEL-Prognostic score (PEL-PS) from an international real-world training set of 59 patients with HIV-associated PEL who received first-line anthracycline-containing chemotherapy from the HIV and AIDS Malignancy Branch at the National Cancer Institute (NCI) in the United States and the National Center for HIV Malignancy at the Chelsea and Westminster Hospital (CWH) in England from 2000 to 2022. We identified prognostic factors associated with overall survival (OS). In a multivariable Cox model, ECOG ≥ 3 (p = 0.007; hazard ratio [HR] = 4.0 [95% CI: 1.5-11.1]) and hemoglobin < 8 g/dL (p = 0.006; HR = 3.8 [95% CI: 1.5-9.7]) were jointly associated with lower survival probability. The resulting PEL-PS separated patients with no negative prognostic factors (score 0: hemoglobin ≥ 8 g/dL and ECOG ≤ 2, 48.1% of patients) with median OS of 10.6 years versus patients with 1-2 negative prognostic factors (score 1-2: hemoglobin < 8 g/dL and/or ECOG ≥ 3, 51.9% of patients) with median OS of 0.8 years (p < 0.0001). The PEL-PS was then validated in 58 patients with HIV-associated PEL treated with first-line anthracycline-containing chemotherapy at Hôpital Saint-Louis in France over the same period: median OS in patients with PEL-PS 0 was 16.9 years versus 0.6 years in patients with PEL-PS score of 1-2 (p < 0.0001). The PEL-PS identifies patients with good and poor prognosis. Patients with poor prognosis may benefit from novel therapies.
引用
- Lurain K, Ramaswami R, Oksenhendler E, et al. Primary Effusion Lymphoma Prognostic Score (PEL-PS): A Validated International Prognostic Score in HIV-Associated Primary Effusion Lymphoma. Am J Hematol. 2025. PMID: 39812325. doi:10.1002/ajh.27580
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。